ZA932455B - Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent - Google Patents

Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent

Info

Publication number
ZA932455B
ZA932455B ZA932455A ZA932455A ZA932455B ZA 932455 B ZA932455 B ZA 932455B ZA 932455 A ZA932455 A ZA 932455A ZA 932455 A ZA932455 A ZA 932455A ZA 932455 B ZA932455 B ZA 932455B
Authority
ZA
South Africa
Prior art keywords
phase
wit
treating cancer
antineoplastic agent
conjunctive therapy
Prior art date
Application number
ZA932455A
Other languages
English (en)
Inventor
Sai P Sunkara
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA932455B publication Critical patent/ZA932455B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA932455A 1992-04-10 1993-04-05 Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent ZA932455B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86639992A 1992-04-10 1992-04-10

Publications (1)

Publication Number Publication Date
ZA932455B true ZA932455B (en) 1993-10-20

Family

ID=25347526

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932455A ZA932455B (en) 1992-04-10 1993-04-05 Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent

Country Status (17)

Country Link
US (2) US20040102461A1 (de)
EP (1) EP0664708B1 (de)
JP (1) JP3713668B2 (de)
KR (1) KR100258668B1 (de)
AT (1) ATE170077T1 (de)
AU (1) AU667527B2 (de)
CA (1) CA2117891C (de)
DE (1) DE69320646T2 (de)
DK (1) DK0664708T3 (de)
ES (1) ES2123642T3 (de)
HU (1) HU219476B (de)
IL (1) IL105329A (de)
MX (1) MX9302038A (de)
NZ (1) NZ251211A (de)
TW (1) TW362971B (de)
WO (1) WO1993020825A1 (de)
ZA (1) ZA932455B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2768295A (en) * 1994-07-11 1996-02-09 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
WO1996001834A1 (en) * 1994-07-12 1996-01-25 Yamasa Corporation 2'-deoxy-2'-(substituted or unsubstituted methylidene)-4'-thionucleoside
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
ES2224430T3 (es) 1997-09-04 2005-03-01 Novoneuron Inc Noribogaina en el tratamiento del dolor y de la toxicomania.
CA2326004A1 (en) 2000-11-02 2002-05-02 Richard E. Jones Methods for treating cellular proliferative disorders
EP1480982A4 (de) * 2002-02-14 2007-08-01 Pharmasset Inc Modifizierte fluorinierte nukleosidanaloga
WO2004042081A1 (de) * 2002-11-04 2004-05-21 Charité-Universitätsme Dizin Berlin Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
CA2806232A1 (en) 2010-07-23 2012-01-26 Demerx, Inc. Noribogaine compositions
EP2481740B1 (de) 2011-01-26 2015-11-04 DemeRx, Inc. Verfahren und Zusammensetzungen zur Herstellung von Noribogain aus Voacangin
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
WO2013112673A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2934541A4 (de) 2012-12-20 2016-08-03 Demerx Inc Substituiertes noribogain
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them

Also Published As

Publication number Publication date
NZ251211A (en) 1997-05-26
AU3813193A (en) 1993-11-18
JPH07505653A (ja) 1995-06-22
AU667527B2 (en) 1996-03-28
IL105329A0 (en) 1993-08-18
TW362971B (en) 1999-07-01
KR100258668B1 (ko) 2000-07-01
EP0664708B1 (de) 1998-08-26
IL105329A (en) 1998-06-15
JP3713668B2 (ja) 2005-11-09
DE69320646D1 (de) 1998-10-01
HU219476B (hu) 2001-04-28
DK0664708T3 (da) 1998-11-02
MX9302038A (es) 1993-10-01
EP0664708A4 (de) 1995-04-24
HU9402914D0 (en) 1995-01-30
US20050032738A1 (en) 2005-02-10
WO1993020825A1 (en) 1993-10-28
KR950700749A (ko) 1995-02-20
HUT71224A (en) 1995-11-28
CA2117891C (en) 1998-07-07
US20040102461A1 (en) 2004-05-27
CA2117891A1 (en) 1993-10-28
ES2123642T3 (es) 1999-01-16
EP0664708A1 (de) 1995-08-02
ATE170077T1 (de) 1998-09-15
DE69320646T2 (de) 1999-01-14

Similar Documents

Publication Publication Date Title
HU9402914D0 (en) Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
GEP20002146B (en) Therapeutic Peptide Derivatives
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
IL114530A0 (en) Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
IL101410A0 (en) Formulation for the treatment of cancer
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
GR3023645T3 (en) Treatment of liver cancer
AU1898792A (en) Treatment or therapeutic booth for energetic, cosmetic and medical purposes
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
ZA932303B (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
AU4042795A (en) Treatment of non-small cell lung carcinoma
NZ268039A (en) Use of efaroxan in treating parkinson's disease
CA2103708A1 (en) Treatment of ovarian cancer
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis
NO943795L (no) Metode for behandling av kreft ved konjunktiv terapi med 2'-halomethylidenderivater og et S-fase eller M-fase-spesifikt antineoplastisk middel
ZA944671B (en) Medicaments for the treatment of inflammatory diseases
AP9000180A0 (en) Pharmaceutical composition for the treatment of protozoal diseases
GB9024181D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
HU910944D0 (en) Apparatus for entering medical preparations by burning or smoking and process for treating the mucoviscidosis diseases
HU904161D0 (en) Medical preparations for treating asthmatic and other diseases attacking the respiratory organs
GB9123572D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy